PL2133091T3 - Kompozycje zawierające supramolekularne układy insuliny użyteczne do leczenia cukrzycy - Google Patents

Kompozycje zawierające supramolekularne układy insuliny użyteczne do leczenia cukrzycy

Info

Publication number: PL2133091T3
Authority: PL; Poland
Prior art keywords: diabetes; compositions; treatment; supramolecular insulin; assemblies useful
Prior art date: 2008-04-07

Application number

PL09155775T

Other languages

English (en)

Inventor

Avadhesha Suriola

Sarika Gupta

Mahendra Pal Singh

Tandrika Chattopadhyay

Original Assignee

Nat Institute Of Immunology

Indian Inst Scient

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-04-07

Filing date

2009-03-20

Publication date

2014-03-31

2009-03-20 Application filed by Nat Institute Of Immunology, Indian Inst Scient filed Critical Nat Institute Of Immunology

2014-03-31 Publication of PL2133091T3 publication Critical patent/PL2133091T3/pl

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
102000004877 Insulin Human genes 0.000 title 1
108090001061 Insulin Proteins 0.000 title 1
230000000712 assembly Effects 0.000 title 1
238000000429 assembly Methods 0.000 title 1
206010012601 diabetes mellitus Diseases 0.000 title 1
229940125396 insulin Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Communicable Diseases (AREA)
Obesity (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL09155775T 2008-04-07 2009-03-20 Kompozycje zawierające supramolekularne układy insuliny użyteczne do leczenia cukrzycy PL2133091T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN914DE2008		2008-04-07
EP09155775.1A EP2133091B1 (en)	2008-04-07	2009-03-20	Compositions comprising supramolecular insulin assemblies useful for the treatment of diabetes

Publications (1)

Publication Number	Publication Date
PL2133091T3 true PL2133091T3 (pl)	2014-03-31

Family

ID=40841040

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL09155775T PL2133091T3 (pl)	2008-04-07	2009-03-20	Kompozycje zawierające supramolekularne układy insuliny użyteczne do leczenia cukrzycy

Country Status (12)

Country	Link
US (3)	US20110034385A1 (pl)
EP (2)	EP2282763B1 (pl)
JP (3)	JP2011516541A (pl)
CN (1)	CN102088997A (pl)
AU (2)	AU2008354530B2 (pl)
CA (1)	CA2720864C (pl)
ES (1)	ES2425491T3 (pl)
HR (1)	HRP20130772T1 (pl)
PL (1)	PL2133091T3 (pl)
PT (1)	PT2133091E (pl)
WO (1)	WO2009125423A2 (pl)
ZA (2)	ZA200902374B (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
EP2280004B1 (en)	1999-06-29	2016-04-20	MannKind Corporation	Pharmaceutical formulations comprising insulin complexed with a diketopiperazine
EP1494732B1 (en)	2002-03-20	2008-01-30	MannKind Corporation	Inhalation apparatus
DK1786784T3 (da)	2004-08-20	2011-02-14	Mannkind Corp	Katalyse af diketopiperazinsyntese
CN104436170B (zh)	2004-08-23	2018-02-23	曼金德公司	用于药物输送的二酮哌嗪盐
AU2006290227B2 (en)	2005-09-14	2012-08-02	Mannkind Corporation	Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
KR20080096809A (ko)	2006-02-22	2008-11-03	맨카인드 코포레이션	디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
DE102006033167A1 (de) *	2006-07-10	2008-01-24	Gelita Ag	Verwendung von Gelatine und einem Vernetzungsmittel zur Herstellung eines vernetzenden medizinischen Klebers
US8785396B2 (en)	2007-10-24	2014-07-22	Mannkind Corporation	Method and composition for treating migraines
KR20100090692A (ko) *	2007-10-24	2010-08-16	맨카인드 코포레이션	활성제의 전달
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
SG10201507036TA (en)	2008-06-13	2015-10-29	Mannkind Corp	A dry powder inhaler and system for drug delivery
EP2609954B1 (en)	2008-06-20	2021-12-29	MannKind Corporation	An interactive apparatus for real-time profiling of inhalation efforts
TWI614024B (zh)	2008-08-11	2018-02-11	曼凱公司	超快起作用胰島素之用途
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
MX2011009512A (es)	2009-03-11	2011-11-29	Mannkind Corp	Aparato, sistema y metodo para medir la resistencia de un inhalador.
MY157166A (en)	2009-06-12	2016-05-13	Mankind Corp	Diketopiperazine microparticles with defined specific surface areas
CA2778698A1 (en)	2009-11-03	2011-05-12	Mannkind Corporation	An apparatus and method for simulating inhalation efforts
IL223742A (en)	2010-06-21	2016-06-30	Mannkind Corp	A dry powder inhaler and preparation for it
EP2694402B1 (en)	2011-04-01	2017-03-22	MannKind Corporation	Blister package for pharmaceutical cartridges
US20140170108A1 (en) *	2011-05-19	2014-06-19	National Institute Of Immunology	Compositions useful for the treatment of inflammatory disease or disorders
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
HK1200318A1 (en)	2011-10-24	2015-08-07	曼金德公司	Methods and compositions for treating pain
WO2013102921A2 (en) *	2011-11-17	2013-07-11	Sanzyme Limited	Hcg - newer treatment modality for type 2 diabetes mellitus (t2dm)
EP2872205B1 (en)	2012-07-12	2017-02-08	MannKind Corporation	Dry powder drug delivery systems
WO2014054046A1 (en) *	2012-10-04	2014-04-10	Gavish-Galilee Bio Applications Ltd	Ordered reversible fibrils, aggregates and multimers of proteins and uses thereof
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
US10159644B2 (en)	2012-10-26	2018-12-25	Mannkind Corporation	Inhalable vaccine compositions and methods
US9707276B2 (en)	2012-12-03	2017-07-18	Merck Sharp & Dohme Corp.	O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
JP2016506401A (ja)	2012-12-21	2016-03-03	サノフイ	二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
WO2014144895A1 (en)	2013-03-15	2014-09-18	Mannkind Corporation	Microcrystalline diketopiperazine compositions and methods
KR102465025B1 (ko)	2013-07-18	2022-11-09	맨카인드 코포레이션	열-안정성 건조 분말 약제학적 조성물 및 방법
EP3030294B1 (en)	2013-08-05	2020-10-07	MannKind Corporation	Insufflation apparatus
EP3080150B1 (en)	2013-12-13	2018-08-01	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
TW201609796A (zh)	2013-12-13	2016-03-16	賽諾菲公司	非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609799A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／ｇｉｐ受體促效劑
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN106977609B (zh) *	2017-04-19	2020-07-28	刘崇东	一种融合蛋白、制备方法及其应用
CN111714643A (zh) *	2019-03-22	2020-09-29	约翰霍普金斯大学	一种单宁酸/Fe3+纳米颗粒体系、药物递送方法
US10799564B1 (en)	2019-05-06	2020-10-13	Baxter International Inc.	Insulin premix formulation and product, methods of preparing same, and methods of using same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5714167A (en) *	1992-06-15	1998-02-03	Emisphere Technologies, Inc.	Active agent transport systems
GB9108634D0 (en) *	1991-04-23	1991-06-12	Ciba Geigy	Pharmaceutical compositions
CO4970787A1 (es) *	1997-12-23	2000-11-07	Lilly Co Eli	Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
FR2786098B1 (fr) *	1998-11-20	2003-05-30	Flamel Tech Sa	Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
US6506724B1 (en) *	1999-06-01	2003-01-14	Amylin Pharmaceuticals, Inc.	Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US20020099013A1 (en) *	2000-11-14	2002-07-25	Thomas Piccariello	Active agent delivery systems and methods for protecting and administering active agents
AU2002248464A1 (en) *	2001-02-21	2002-09-12	Medtronic Minimed, Inc.	Stabilized insulin formulations
FR2822834B1 (fr) *	2001-04-02	2005-02-25	Flamel Tech Sa	Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
US7655618B2 (en) *	2002-12-27	2010-02-02	Diobex, Inc.	Compositions and methods for the prevention and control of insulin-induced hypoglycemia
JP4936884B2 (ja) *	2003-06-03	2012-05-23	ノボ・ノルデイスク・エー／エス	安定化された薬学的ペプチド組成物
CN101415724B (zh) *	2003-06-30	2015-12-02	特拉维夫大学未来科技开发有限公司	肽、抗肽抗体以及用它们来诊断和治疗淀粉样蛋白相关疾病的方法
EP1824460B1 (en) *	2004-11-10	2014-12-24	Tolmar Therapeutics, Inc.	A stabilized polymeric delivery system
US20060281669A1 (en) *	2005-06-13	2006-12-14	Yue Samuel K	Method and compositions for the treatment of diabetes and related complications
US8759290B2 (en) *	2005-10-18	2014-06-24	Biocon Limited	Oral glucagon-like peptide conjugates for metabolic diseases
US20070148131A1 (en) *	2005-12-05	2007-06-28	Trinity Biosystems, Inc.	Methods and compositions for needleless delivery of binding partners
US8440214B2 (en) *	2006-01-31	2013-05-14	Boston Scientific Scimed, Inc.	Medical devices for therapeutic agent delivery with polymeric regions that contain copolymers having both soft segments and uniform length hard segments
US20100184659A1 (en) *	2006-12-21	2010-07-22	Warren Jaworowicz	Sustained-Release Formulations Comprising Crystals, Macromolecular Gels, and Particulate Suspensions of Biologic Agents

2008
- 2008-10-13 CA CA2720864A patent/CA2720864C/en not_active Expired - Fee Related
- 2008-10-13 CN CN2008801296299A patent/CN102088997A/zh active Pending
- 2008-10-13 US US12/936,709 patent/US20110034385A1/en not_active Abandoned
- 2008-10-13 JP JP2011503551A patent/JP2011516541A/ja active Pending
- 2008-10-13 AU AU2008354530A patent/AU2008354530B2/en not_active Ceased
- 2008-10-13 WO PCT/IN2008/000664 patent/WO2009125423A2/en not_active Ceased
- 2008-10-13 EP EP08873840.6A patent/EP2282763B1/en not_active Not-in-force
2009
- 2009-03-06 AU AU2009200906A patent/AU2009200906B2/en not_active Ceased
- 2009-03-20 PL PL09155775T patent/PL2133091T3/pl unknown
- 2009-03-20 ES ES09155775T patent/ES2425491T3/es active Active
- 2009-03-20 EP EP09155775.1A patent/EP2133091B1/en not_active Not-in-force
- 2009-03-20 PT PT91557751T patent/PT2133091E/pt unknown
- 2009-04-02 JP JP2009090219A patent/JP5592077B2/ja not_active Expired - Fee Related
- 2009-04-06 ZA ZA200902374A patent/ZA200902374B/xx unknown
- 2009-04-07 US US12/419,669 patent/US8426362B2/en not_active Expired - Fee Related
2010
- 2010-10-06 ZA ZA2010/07114A patent/ZA201007114B/en unknown
2013
- 2013-03-18 US US13/845,209 patent/US8940691B2/en not_active Expired - Fee Related
- 2013-08-16 HR HRP20130772AT patent/HRP20130772T1/hr unknown
2014
- 2014-08-28 JP JP2014173649A patent/JP5964373B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP2282763B1 (en)	2013-12-11
EP2282763A2 (en)	2011-02-16
EP2133091A2 (en)	2009-12-16
HRP20130772T1 (hr)	2013-12-06
US20090258818A1 (en)	2009-10-15
PT2133091E (pt)	2013-08-28
AU2009200906B2 (en)	2014-04-03
JP5592077B2 (ja)	2014-09-17
EP2133091A3 (en)	2010-07-14
AU2008354530A1 (en)	2009-10-15
AU2008354530B2 (en)	2014-02-27
CA2720864C (en)	2017-07-04
US20110034385A1 (en)	2011-02-10
ZA200902374B (en)	2009-12-30
CA2720864A1 (en)	2009-10-15
ES2425491T3 (es)	2013-10-15
US8940691B2 (en)	2015-01-27
JP2009249382A (ja)	2009-10-29
ZA201007114B (en)	2011-06-29
EP2133091B1 (en)	2013-05-22
WO2009125423A2 (en)	2009-10-15
JP2011516541A (ja)	2011-05-26
US8426362B2 (en)	2013-04-23
US20130217621A1 (en)	2013-08-22
JP2014231520A (ja)	2014-12-11
AU2009200906A1 (en)	2010-03-25
WO2009125423A3 (en)	2010-03-04
CN102088997A (zh)	2011-06-08
JP5964373B2 (ja)	2016-08-03

Publication	Publication Date	Title
ZA200902374B (en)	2009-12-30	Compositions useful for the treatment of diabetes
ZA201006367B (en)	2011-05-25	Oxadiazoanthracene compounds for the treatment of diabetes
IL225198A (en)	2016-02-29	Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
GB0802403D0 (en)	2008-03-12	Compositions for the treatment of oxidative stress
ZA201006827B (en)	2011-05-25	Carboxamide-heteroaryl derivatives for the treatment of diabetes
PL2247602T3 (pl)	2013-08-30	Pochodne O-glukuronido-adamantylowe jako inhibitory dipeptydylopeptydazy IV do leczenia cukrzycy
ZA200905970B (en)	2012-08-29	Pharmaceutical composition for treatment of diabetic complications
IL211313A0 (en)	2011-04-28	Compounds, compositions and methods for the treatment of ??-amyloid diseases and synucleinopathies
PT2315587T (pt)	2018-01-31	Produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan
IL199829A0 (en)	2010-04-15	Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
IL206904A0 (en)	2010-12-30	Beta--amino acid derivatives for treatment of diabetes
IL209723A0 (en)	2011-02-28	Tetrahydrocinnolines as 11 beta hsd1 inhibitors for diabetes
EP2320879A4 (en)	2014-03-05	PHARMACEUTICAL COMPOSITION COMPRISES JASMONATES
GB0812019D0 (en)	2008-08-06	Insulin
IL211267A0 (en)	2011-04-28	Oxadiazole derivatives for the treatment of diabetes
AU2009215883A8 (en)	2010-09-09	Blood substitute solution
PL2323625T3 (pl)	2017-01-31	Nowa kompozycja do leczenia pigmentacji wybroczynowych
IL209947A (en)	2014-07-31	Compounds for the treatment of corneal inflammation
IL207668A0 (en)	2010-12-30	Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
PL2252302T3 (pl)	2014-05-30	Kompozycja do leczenia zapalenia kości i stawów
IL200192A0 (en)	2010-04-15	Composition useful for the treatment of type 2 diabetes
EP2402342A4 (en)	2012-09-19	PHARMACEUTICAL COMPOSITION FOR TREATING TYPE 2 DIABETES
ZA201100529B (en)	2012-03-28	Solid pharmaceutical composition comprising exemestane
EP2352541A4 (en)	2014-01-08	CATHETER LOCK COMPOSITION
PL384259A1 (pl)	2009-07-20	Kompozycja farmaceutyczna do leczenia chorób skórnych